A Phase Ib/II Trial of Combined BRAF and EGFR Inhibition in BRAF V600E Positive Metastatic Colorectal Cancer and Other Cancers: The EVICT (Erlotinib and Vemurafenib In Combination Trial) Study.

Lavinia Tan Ben Tran Jeanne Tie Benjamin Markman Sumi Ananda Niall C Tebbutt Michael Michael Emma Link Stephen Q Wong Sushma Chandrashekar Jerick Guinto David S Ritchie Rachel M Koldej Benjamin J Solomon Grant A McArthur Rodney John Hicks Peter Gibbs Sarah-Jane Dawson Jayesh Desai

Published in: Clinical cancer research : an official journal of the American Association for Cancer Research (2023)

The Erlotinib and Vemurafenib In Combination Trial study demonstrated a safe and novel combination of two oral inhibitors targeting BRAF and EGFR. The dynamic assessment of serial ctDNA was a useful measure of underlying genomic changes in response to this combination and in understanding potential mechanisms of resistance.

Keyphrases

metastatic colorectal cancer
epidermal growth factor receptor
small cell lung cancer
study protocol
clinical trial
phase iii
phase ii
tyrosine kinase
advanced non small cell lung cancer
randomized controlled trial
cancer therapy
drug delivery
climate change
circulating tumor cells